Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc

July 28, 2005 12:00 ET

Shire Acquisition Inc. Declares Dividend

MONTREAL, QUEBEC--(CCNMatthews - July 28, 2005) - The Board of Directors of Shire Pharmaceuticals Group plc (Shire) (TSX:SHQ)(NASDAQ:SHPGY)(LSE:SHP) has resolved to pay a dividend of pounds sterling 0.010475 (1.0475 pence) per ordinary share in respect of the six months ended June 30, 2005.

In accordance with arrangements put in place at the time of Shire's merger with BioChem Pharma Inc., the Board of Directors of Shire Acquisition Inc. (Corporation) (TSX:SHQ) has resolved to pay an equivalent dividend of C$0.067629 (6.7629 Canadian cents)(i) per Exchangeable Share. The dividend will be paid on October 13, 2005 to exchangeable shareholders of record as of September 16, 2005. Such payment date and record date correspond to the payment date and record date, respectively, for the dividend on Shire's ordinary shares. The dividend amount for each Exchangeable Share is calculated in accordance with the terms and conditions set out in the Corporation's articles.

(i)Exchange rate: GBP1:C$2.1520 (being the noon spot exchange rate for GBP as reported by the Bank of Canada on July 27, 2005)


Shire Acquisition Inc.

Shire Acquisition Inc. (Corporation) is an indirect wholly owned subsidiary of Shire Pharmaceuticals Group plc (Shire). Exchangeable Shares in the Corporation are listed on the Toronto Stock Exchange. Exchangeable Shares are convertible into three ordinary shares of Shire or one ADS representing three ordinary shares of Shire. Shire's ordinary shares are listed on the London Stock Exchange and Shire's ADSs are listed on NASDAQ.

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US. For further information on Shire, please visit the Company's website:

Contact Information

  • Shire Pharmaceuticals Group plc
    Brian Piper (US and Canada)
    (484) 595-8252
    Shire Pharmaceuticals Group plc
    Clea Rosenfeld (Rest of the World)
    +44 1256 894 160
    Shire Pharmaceuticals Group plc (medias)
    Matthew Cabrey (US and Canada)
    (484) 595-8248
    Shire Pharmaceuticals Group plc (medias)
    Jessica Mann (Rest of the World)
    +44 1256 894 280